Full Press Release Details
Ocugen Granted FDA Orphan Drug Designation for OCU400 (NR2E3) Gene Therapy for the Treatment of CEP290 Mutation Associated Retinal Disease.
OCGN
Ocugen Granted FDA Orphan Drug Designation for OCU400 (NR2E3) Gene Therapy for the Treatment of CEP290 Mutation Associated Retinal Disease
Key Takeaway: Ocugen Granted FDA Orphan Drug Designation for OCU400 (NR2E3) Gene Therapy for the Treatment of CEP290 Mutation Associated Retinal Disease